APHL seeks to identify and select one state or local public health laboratory that will perform hepatitis C virus (HCV) nucleic acid testing (NAT) in a regional shared service model.


The recommended testing algorithm for diagnosis of current HCV infection comes from the 2013 Guidance. All persons who test positive for an HCV antibody (anti-HCV) test should receive a HCV nucleic acid test (NAT) to detect HCV RNA.

To determine the best approach to assist laboratories in expanding access to HCV NAT in a cost effective and timely manner, APHL is seeking proposals for test sharing models that would provide HCV NAT on qualified specimens (anti-HCV positive) to PHLs in neighboring jurisdictions.

Proposals will be evaluated based on the laboratory's existing capability and facilities and applicants must have:

  • Established capacity for diagnostic HCV NAT; and
  • Established capacity for providing testing for outside PHLs including data transfer and specimen receipt and processing; and
  • Sufficient equipment, laboratory space and workforce capacity for the proposed workload


March 20, 2017                  –             RFP Issued

April 15, 2017                                  Letter of Intent Due to APHL (see RFP)

May 15, 2017                                   RFP Responses Due

June 2, 2017                       –             Proposal review completed

June 5-16, 2017                 –             If needed, follow-up interviews and updated proposals due

June 21, 2017                     –             Final review completed and awardees selected

June 30, 2017                     –             Draft contracts submitted to APHL Legal Dept. for final internal review


Any modification to this anticipated schedule will be posted here (www.aphl.org/rfp) and via an email blast to the public health laboratories (PHLs).

Request for Proposal Materials

The Expansion of Hepatitis C Virus (HCV) Nucleic Acid Testing (NAT) RFP provides details on how to complete this RFP. The RFP contains a copy of the scoring criteria that will be used for evaluation of proposals in Appendix C. The details for expectations for HCV NAT testing are contained in Appendix A.  


"On page five (5) of the RFP, under section "Post-Evaluation Procedures," the following updates the first sentence of paragraph." 

The selected laboratory will be notified by APHL staff within ten business days of the completion of the evaluation and the name of the recipient will be posted to APHL’s procurement website, www.aphl.org/rfp on the same day.

Questions and Answers

Is this a federal grant and if so is there a CFDA number? Who is the funder?

Is an HCV Viral Load assay (which does not have a diagnostic claim) an acceptable method for this application?

Is the applicant required to create the region or will APHL be involved in that process?

Do the partner/collaborating jurisdictions need to be physical neighbors?